A CGP assay that detects more than 700 cancer-relevant gene variants and molecular signatures, gives researchers new insights into tumour biology, expanding the potential for personalized cancer ...
We performed a single-institution, retrospective analysis of CGP utilization and treatment patterns in patients with localized PDAC who underwent curative-intent resection in the contemporary period ...
CGP identifies TP53 and SMAD4 mutations as negative prognostic markers, while PTEN mutations correlate with improved survival in CRC patients. Despite no significant survival advantage, CGP-guided ...
Summit™ 2.0 is a CSF-based liquid biopsy assay designed to enable comprehensive genomic profiling for characterization of CNS tumors. CNS malignancies present unique diagnostic challenges, as ...
Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Level Evidence NASHIK, India, May 14, 2026 ...
“The broad capabilities of the OncoExTra assay detected therapeutically actionable and other clinically relevant genomic events that can inform clinical decision-making for patients with advanced ...
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its ...
Foundation Medicine tallied another nod from the FDA for one of its genomic profiling tests that searches for specific ...
—A team of researchers in Tokyo recently took on the challenge of attempting to determine whether comprehensive genomic profiling has clinical utility in a large cohort of patients with non-small cell ...
Precision medicines and personalized treatments are revolutionizing cancer therapy. Small molecules, biological agents, antibody-drug conjugates and cell-based therapies directed against specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results